NCT03319212

Clinical Characterization of Symptomatic Populations

Name: Clinical Trial NCT03319212
Creator: Johnson & Johnson Vision Care, Inc.
Keywords: Ametropia, senofilcon A contact lenses, device, clinical trial, Canada,United States of America

Johnson & Johnson Vision Care, Inc.·ClinicalTrials.gov·device·Device trialCompleted

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Ametropia
Drug/Device/Intervention: senofilcon A contact lenses
Study type: Interventional
Intervention type: device

Sponsor & location

Primary sponsor: Johnson & Johnson Vision Care, Inc.
Location: Jacksonville,Waterloo, Canada,United States of America

Timeline & enrollment

Phase: N/A
Start date: Sep 29, 2017
End date: Aug 15, 2018
Enrollment: 105 participants

Primary outcome

Meibomian Gland Imaging,Meibomian Gland Expressibility,Lid Margin Evaluation: Number of Eyes With Abnormal Biomicroscopy Findings,Lid Wiper Epitheliopathy,Conjunctival Folds

Summary

This is an unmasked, non-randomized, single arm, stratified, dispensing investigation of symptomatic and asymptomatic subject populations. Subjects will be assigned to a single study lens type to be worn bilaterally for approximately 4 weeks followed by no contact lens wear for 1 week.

ICD-10 classifications

Amblyopia ex anopsiaAmoebiasisAmoebiasis, unspecifiedMyoclonusOesophagitis

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT03319212
Type: Device Trial

About this record

Access comprehensive clinical trial information for NCT03319212 through Pure Global AI's free database. This phase not specified trial is sponsored by Johnson & Johnson Vision Care, Inc. and is currently Completed. The study focuses on Ametropia. Target enrollment is 105 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.